An Extension Study of Subcutaneous Secukinumab to Evaluate the Long-term Efficacy, Safety and Tolerability up to 4 Years in Patients With Juvenile Idiopathic Arthritis Subtypes of Juvenile Psoriatic Arthritis and Enthesitis Related Arthritis
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
Optional open label, roll over extension study to investigate the efficacy and safety of secukinumab treatment in Juvenile Idiopathic Arthritis (JIA) subtypes of Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA).
Juvenile Psoriatic Arthritis
Enthesitis Related Arthritis
Oct 01, 2020
Jun 07, 2019
Nov 27, 2024
2 Years and older (Child, Adult, Older Adult)
Secukinumab (AIN457) is a high-affinity fully human monoclonal anti- human antibody that target IL-17A and neutralizes activity.
Patient must have participated in core study CAIN457F2304, and must have completed the entire treatment period up to and including Week 104.
Patients must be deemed by the investigator to benefit from continued secukinumab therapy.
Plans for administration of live vaccines during the extension study period.
Any patient taking other concomitant biologic immunomodulating agent(s) except secukinumab.
Any patient who is deemed not to be benefiting from the study treatment based upon lack of improvement or worsening of their symptoms.
All other protocol related inclusion/exclusion criteria will apply.